Many researchers have investigated the potential of CAR T-cell treatment in the context of melanoma, focusing on the frequently expressed gp100 and MART-1 antigens . As of 2019, with some patients exhibiting sustained remission and persistent clinical improvements, efforts in investigating CAR T-cell therapy have produced promising results, suggesting that this therapy may play a pivotal role in this tough cancer . However, to fully realize its potential, the use of CAR T-cell therapy in solid malignancies (like melanoma) must overcome a set of hindrances . The intricate microenvironment of the tumor can present significant challenges to the efficacy of CAR T-cell therapy because of its immunosuppressive nature and physical barriers that prevent penetration by the T-cell . In addition, there is still more to be researched in the areas of target antigen selection, tumor heterogeneity mitigation, and antigen escape strategy development . Despite these setbacks, CAR T-cell treatment for melanoma is continually developing, with professionals looking into enhancing T-cell functionality, transport, and persistence within the tumor's environment . With a growing understanding of the immunological landscape and the underlying fundamentals behind melanoma, there is increasing hope that CAR T-cell therapy will surface as a transformational treatment approach to this disease .